Erowid References Database
|
Lynch JJ, Wade CL, Mikusa JP, Decker MW, Honore P.
“ABT-594 a nicotinic acetylcholine agonist: anti-allodynia in a rat chemotherapy-induced pain model”.
Eur J Pharmacol. 2005 Feb 16;509(1):43-8.
|
|
Abstract
ABT-594 R-5-2-azetidinylmethoxy-2-chloropyridine represents a novel class of broad-spectrum analgesics whose primary mechanism of action is activation of the neuronal nicotinic acetylcholine receptors. The present study characterized the effects of ABT-594 in a rat chemotherapy-induced neuropathic pain model, where it attenuated mechanical allodynia with an ED50 = 40 nmol/kg i.p.. This anti-allodynic effect was not blocked by systemic i.p. pretreatment with naloxone but was blocked completely with mecamylamine. Pretreatment with chlorisondamine 0.2-5 micromol/kg, i.p. only partially blocked the effects of ABT-594 at the higher doses tested. In contrast, central i.c.v. pretreatment with chlorisondamine completely blocked ABT-594's anti-allodynic effect. Taken together, the data demonstrate that ABT-594 has a potent anti-allodynic effect in the rat vincristine model and that, in addition to its strong central site of action, ABT-594's effects are partially mediated by peripheral nicotinic acetylcholine receptors in this animal model of chemotherapy-induced neuropathic pain.
|
| # |
| Submit Comment |
|
[
Cite HTML ]
